ATXS · As filed with the SEC
Astria Therapeutics balance sheet, by fiscal year
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 | Dec 31, 2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 | FY2017 Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| Statement | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 59,820,000 | 175,530,000 | 20,525,000 | 86,508,000 | 24,930,000 | 9,899,000 | 15,294,000 | 16,369,000 |
| Short-term investments | 268,312,000 | 71,000,000 | 205,912,000 | 39,000,000 | 20,000,000 | 26,345,000 | 22,276,000 | — |
| Prepaid expenses and other current assets | 6,511,000 | 4,412,000 | 1,253,000 | 1,567,000 | 1,395,000 | 2,714,000 | 1,345,000 | 1,094,000 |
| Total current assets | 334,643,000 | 250,942,000 | 227,690,000 | 127,075,000 | 46,325,000 | 38,958,000 | 38,915,000 | 17,463,000 |
| Property and equipment, net | — | — | — | — | — | — | 56,000 | 321,000 |
| Restricted cash | — | — | — | — | — | — | 113,000 | 113,000 |
| Right-of-use asset | 5,114,000 | 363,000 | 948,000 | 394,000 | 966,000 | 2,349,000 | — | — |
| Other assets | 2,606,000 | 3,361,000 | 1,995,000 | 45,000 | 165,000 | 473,000 | 85,000 | — |
| Total assets | 342,363,000 | 254,666,000 | 230,633,000 | 127,514,000 | 47,456,000 | 41,780,000 | 39,169,000 | 17,897,000 |
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 4,320,000 | 1,513,000 | 788,000 | 1,557,000 | 1,544,000 | 1,197,000 | 1,408,000 | 773,000 |
| Accrued expenses | 13,427,000 | 9,708,000 | 7,690,000 | 3,281,000 | 4,197,000 | 2,610,000 | 2,763,000 | 2,432,000 |
| Current portion of notes payable, net of discount | — | — | — | — | — | — | — | 2,479,000 |
| Other liability | — | — | — | — | — | — | — | 332,000 |
| Current portion of operating lease liabilities | 1,384,000 | 329,000 | 582,000 | 365,000 | 649,000 | 1,225,000 | — | — |
| Total current liabilities | 19,131,000 | 11,550,000 | 9,060,000 | 5,203,000 | 6,390,000 | 5,032,000 | 4,171,000 | 6,016,000 |
| Deferred rent, net of current portion | — | — | — | — | — | — | 9,000 | 89,000 |
| Other long-term liabilities | — | — | — | — | — | — | 47,000 | — |
| Long-term portion of operating lease liabilities | 3,969,000 | — | 357,000 | — | 397,000 | 1,028,000 | — | — |
| Total liabilities | 23,100,000 | 11,550,000 | 9,417,000 | 5,203,000 | 6,787,000 | 6,060,000 | 4,227,000 | 6,105,000 |
| Stockholders' equity: | ||||||||
| Series X Preferred Stock | — | — | — | 96,398,000 | — | — | — | — |
| Common stock, $0.001 par value per share, 150,000,000 shares authorized; 56,434,219 and 41,034,797 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 57,000 | 41,000 | 28,000 | 13,000 | 4,000 | 12,000 | 7,000 | 24,000 |
| Additional paid-in capital | 898,513,000 | 728,285,000 | 632,512,000 | 481,709,000 | 301,562,000 | 259,305,000 | 232,243,000 | 183,202,000 |
| Accumulated other comprehensive gain | 163,000 | — | (79,000) | — | — | — | (4,000) | — |
| Accumulated deficit | (674,794,000) | (580,534,000) | (507,643,000) | (455,809,000) | (260,897,000) | (223,597,000) | (197,304,000) | (171,434,000) |
| Total stockholders' equity | 319,263,000 | 243,116,000 | 221,216,000 | 122,311,000 | 40,669,000 | 35,720,000 | 34,942,000 | 11,792,000 |
| Total liabilities and stockholders' equity | 342,363,000 | 254,666,000 | 230,633,000 | 127,514,000 | 47,456,000 | 41,780,000 | 39,169,000 | 17,897,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.